TORONTO, Sept. 17, 2018 /PRNewswire/ – MDBriefCase Group Inc. (the “Company” or “MDBriefCase“), a leading provider of online continuing professional development for physicians, pharmacists, nurses, and other allied healthcare professionals in Canada, Australia, the Middle East, Africa, and around the world, is pleased to announce the appointment of Jason Flowerday as Chief Executive Officer (“CEO“).

As an executive and an entrepreneur, Flowerday brings more than two decades of industry experience focusing on operations management, business development, and strategy. “I’m extremely excited about the opportunity to lead the world-class team at MDBriefCase,” said Flowerday. “With a proven track record created over the past 17 years, and more than 170,000 members worldwide, MDBriefCase is in a great position to deliver new and exciting continuing medical education to improve patient care on a global scale.”

Since 2001, MDBriefCase has delivered interactive, peer-reviewed, evidence-based programs free of charge on its proprietary learning management system. MDBriefCase is the leading provider of online accredited medical education in Canada and has also established a leading presence in the Australian market after opening an additional location in Sydney in 2012.

The key to its success is the strong partnerships MDBriefCase has with several prestigious medical organizations around the world. In Canada, the company has over 20 long-standing partnerships including the recently formed collaborations between the Royal College of Physicians and Surgeons of Canada, the Canadian Nurses Association, the Canadian Thoracic Society, and the Canadian Society of Endocrinology and Metabolism. These partnerships allow MDBriefCase to provide the latest guidelines and information, as well as increasing the breadth of content for each profession and specialty.

Internationally, MDBriefCase has expanded to deliver learning content for healthcare professionals in 16 countries around the world. Alongside programs available in Europe and the United States, MDBriefCase offers programs to members in emerging markets such as Africa, the Middle East, Central and South America, and Asia. All programs are locally adapted to reflect the practices, treatments and therapies available in those regions. MDBriefCase is proud to establish recent partnerships with several renowned organizations such as the King Fahad Medical City (Saudi Arabia), the Imperial College London Diabetes Centre (Abu Dhabi), the Royal College of General Practitioners (United Kingdom), and the International Society of Endocrinology.

“We are fully committed to supporting MDBriefCase as the Company continues its global expansion strategy,” added John Trang, Partner at Persistence Capital Partners, private equity partners of MDBriefCase. “I’m excited about Jason’s addition to the organization and what we will achieve together, in partnership with some of the most respected medical organizations in the world.”

Before joining MDBriefCase, Flowerday held CEO positions at 3D Signatures Inc., a publicly traded, personalized medical software company, Pro Bono Bio Inc., a biotechnology and medical device company based in the United Kingdom and Knight Therapeutics Inc. Previously, he spent over a decade at Bayer Healthcare and Ortho Biotech before co-founding and selling a pair of successful start-ups, which included a digital healthcare medical education company.

Flowerday’s academic credentials include a B.Sc. from the University of Toronto and an MBA from the Queen’s School of Business. 

About MDBriefCase Group

MDBriefCase Group Inc. specializes in developing online, accredited continuing professional development for healthcare professionals. The company partners with prestigious regional and international medical associations to ensure its innovative education programs reflect the local experiences of healthcare professionals around the world. Its programs are peer-reviewed by clinical specialists to ensure balance and applicability to practice. Over 170,000 healthcare professionals have free access to the latest evidence-based information and guidelines to improve local patient care. For more information, visit the company’s website at: 

About Persistence Capital Partners

Persistence Capital Partners is Canada’s leading private equity fund exclusively focused on high-growth opportunities in the healthcare field. With deep healthcare industry expertise, PCP aims to create significant long-term capital appreciation for its investors by identifying and developing attractive investment opportunities in the Canadian healthcare market. PCP has offices in Montreal, Quebec, and Toronto, Ontario.

SOURCE MDBriefCase Group Inc.

Related Links

Recent Posts

Further Education

Learning and Development

The Rising Prevalence of Skin Cancer in Canada

Posted 26 May 22

Further Education

Learning and Development

Digital Healthcare 101: What is Digital Medicine?

Posted 10 May 22

Further Education

New Chapter in Digital Health: e-Prescribing

Posted 17 Mar 22